Research and Development: Comparing Key Metrics for PTC Therapeutics, Inc. and Perrigo Company plc

R&D Investment Trends in Biopharma: PTC vs. Perrigo

__timestampPTC Therapeutics, Inc.Perrigo Company plc
Wednesday, January 1, 201479838000152500000
Thursday, January 1, 2015121816000187800000
Friday, January 1, 2016117633000184000000
Sunday, January 1, 2017117456000167700000
Monday, January 1, 2018171984000218600000
Tuesday, January 1, 2019257452000187400000
Wednesday, January 1, 2020477643000177700000
Friday, January 1, 2021540684000122000000
Saturday, January 1, 2022651496000123100000
Sunday, January 1, 2023666563000122500000
Loading chart...

Unleashing insights

A Decade of Innovation: R&D Trends in Biopharma

In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, PTC Therapeutics, Inc. and Perrigo Company plc have demonstrated contrasting R&D investment strategies. PTC Therapeutics has shown a remarkable growth trajectory, with R&D expenses increasing by over 730% from 2014 to 2023. This surge underscores their commitment to pioneering new therapies. In contrast, Perrigo Company plc's R&D spending has remained relatively stable, peaking in 2018 and then declining by approximately 44% by 2023. This divergence highlights differing strategic priorities: PTC's aggressive pursuit of innovation versus Perrigo's focus on optimizing existing product lines. As the biopharma industry continues to advance, these investment patterns offer valuable insights into the future direction of these companies and their potential impact on healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025